Search results
Showing 121 to 135 of 1037 results for criteria
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults.
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.
Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
NICE health technology evaluation topic selection: the manual (PMG37)
This is not the current manual. From 29 May 2024, health technologies are selected using the new NICE-wide topic prioritisation process (PMG46)
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults.
Venetoclax for treating chronic lymphocytic leukaemia (TA796)
Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms in myelofibrosis in adults.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Evidence-based recommendations on AposHealth for knee osteoarthritis.
View recommendations for MTG76Show all sections
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults.
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.